Clinical trial · Interventional
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
An Open-Label, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
NCT00517920CI-TRIAL-00008784completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ABT-869 | Drug | Linifanib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ABT-869
- interventionNames
- Drug: ABT-869
Primary outcomes (2)
- measure
- Progression-Free Rate
- timeFrame
- Week 16
- measure
- Objective Response Rate
- timeFrame
- Week 16
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * Subject must be greater than or equal to 18 years of age * Subject must be diagnosed with unresectable or metastatic HCC * Subjects must have a measurable lesion by RECIST on CT scan in at least one site which has not received radiation * Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2 * No other active malignancy within the past 5 years Exclusion Criteria * Subject has received targeted VEGF/PDGF/TKI therapy. Prior Avastin is allowed * Subject has Child-Pugh grade Class C hepatic impairment * The subject has proteinuria Common Toxicity Criteria (CTC) grade \> 1 as measured by routine urinalysis or 24 hour urine collection during screening assessment * Subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure \> 100 mmHg or systolic blood pressure \> 150 mmHg. Subjects may be re-screened if blood pressure is shown to be controlled with or without intervention * The subject has a documented left ventricular Ejection Fraction \< 50% * Subject is receiving therapeutic anticoagulation therapy
References
Publications (0)
Data not yet available
No reference posted for this study.